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A B S T R A C T   
COVID-19 is the cause of a pandemic associated with substantial morbidity and mortality. As yet, there is no 
available approved drug to eradicate the virus. In this review article, we present an alternative study area that 
may contribute to the development of therapeutic targets for COVID-19. Growing evidence is revealing further 
pathophysiological mechanisms of COVID-19 related to the disregulation of inflammation pathways that seem to 
play a critical role toward COVID-19 complications. 
The NF-kB and JAK/STAT signaling pathways are highly activated in acute inflammation, and the excessive 
activity of these pathways in COVID-19 patients likely exacerbates the inflammatory responses of the host. A 
group of non-coding RNAs (miRNAs) manage certain features of the inflammatory process. In this study, we 
discuss recent advances in our understanding of miRNAs and their connection to inflammatory responses. 
Additionally, we consider the link between perturbations in miRNA levels and the onset of COVID-19 disease. 
Furthermore, previous studies published in the online databases, namely web of science, MEDLINE (PubMed), 
and Scopus, were reviewed for the potential role of miRNAs in the inflammatory manifestations of COVID-19. 
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kinase; STAT, Signal transducers and activators of transcription; IL-1, Interleukin-1; IL-6, Interleukin-6; IL-8, Interleukin-8; IL-21, Interleukin-21; TNF-β, Tumor 
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Moreover, we disclosed the interactions of inflammatory genes using STRING DB and designed interactions 
between miRNAs and target genes using Cityscape software. Several miRNAs, particularly miR-9, miR-98, miR- 
223, and miR-214, play crucial roles in the regulation of NF-kB and JAK-STAT signaling pathways as inflam-
matory regulators. Therefore, this group of miRNAs that mitigate inflammatory pathways can be further 
regarded as potential targets for far-reaching-therapeutic strategies in COVID-19 diseases.   
1. Introduction 
The coronavirus disease 2019 (COVID-19) is the cause of morbidity 
and mortality, which is associated with severe acute respiratory syn-
drome coronavirus-2 (SARS-CoV-2) infection that is characterized by 
acute respiratory failure. Usually, COVID-19 is manifested as a mild 
respiratory disease, although it can occasionally lead to severe alveolar 
inflammation. Lung histopathological findings of patients with COVID- 
19 showed extensive alveolar damaging via widespread infiltration of 
immune cells, thrombosis of pulmonary vessels and fibrin deposits 
[8;44]. 
In patients with COVID-19, an excessive or uncontrolled innate im-
mune response leads to a cytokine storm and acute respiratory distress 
syndrome (ARDS). Infected macrophages with COVID-19 present 
COVID-19 antigens to T cells. Activated T cells produce cytokines that 
are associated with different T cell subtypes, and following the release of 
large quantities of cytokines, there is immune response amplification. In 
response to COVID-19 infection, the secretion of massive chemokines 
and cytokines like Interleukin-1 (IL-1), Interleukin-6 (IL-6), Interleukin- 
8 (IL-8), Interleukin-21 (IL-21), tumor necrosis factor-beta (TNF-β), and 
monocyte chemoattractant protein-1 (MCP-1) is promoted in infected 
cells. Afterward, these chemokines and cytokines, in turn, recruit lym-
phocytes and leukocytes to the infection site. CD8 T cells produce very 
effective mediators to destroy COVID-19, but the continued release of 
these mediators led to viral persistence and a negative effect on CD8 T 
cell activation [15]. 
S protein of COVID-19 attaches to dipeptidyl peptidase-4 receptor 
(DPP4R) on the host cell and leads to the appearance of genomic RNA 
(dsRNA) in the cytoplasm of the host cell. Toll-like receptor 3 (TLR-3) 
sensitized by dsRNA and signaling cascades of interferon-regulatory 
factors (IRFs) and nuclear factor-kB (NF-kB) are activated and then 
produced interferons (IFNs) (IFN-I, IFN-II, and IFN-III) and pro- 
inflammatory cytokines. The engagement of IFN (I and III) receptors 
induced different members of the Janus kinase (JAK) and signal trans-
ducer and activator of transcription (STAT) families and also helped 
form specific transcription factor complexes. In contrast, IFN-II acti-
vated JAK1 and JAK2, producing a phosphorylated STAT1 homodimer 
[88]. 
Small molecules (17–24nt) of non-coding RNAs known as miRNAs 
regulate the post-transcriptional expression thought to block the target 
genes by binding to the 3′UTR during transcription, repressing the 
messenger RNA, and promoting their degradation by cleavage in various 
cellular processes, such as cell proliferation, apoptosis, and differentia-
tion. More than two thousand miRNAs have been identified in humans. 
One miRNA targets several genes, while one gene is targeted by multiple 
miRNAs. Some miRNAs are produced during viral infection, modulating 
the function of the immune response against respiratory viruses [2,88]. 
This review will analyze the role of miRNAs in the regulation of immune 
response against COVID-19 especially inflammatory pathway based on 
bioinformatics prediction. 
2. The role of JAK/STAT and NF-kB signaling pathways during 
viral infections particularly SARS-CoV-2 
The renin–angiotensin–system (RAS) is a cascade, which results in 
the conversion of the inactive decapeptide angiotensin I (Ang I) into the 
active peptide angiotensin II (Ang II). The initial enzyme in the cascade 
is renin, an aspartic proteinase, which cleaves the amino terminus of the 
angiotensinogen, thereby releasing the decapeptide pro-hormone Ang I. 
Angiotensin-converting enzyme (ACE) removes two additional amino 
acids to yield the active octapeptide hormone Ang II [103]. Ang II exerts 
its actions via the (JAK-STAT) signaling pathway, which leads to vaso-
constriction, hypertension, and chronic tissue injury [3,75]. Renin- 
Angiotensin system mediates pro-inflammatory cytokine production. 
Indeed, Ang II increases the infiltration of immune cells, which, in turn, 
augments the local production of pro-inflammatory cytokines such as 
interferon (IFN)-γ, IL-1, IL-6, and tumor necrosis factor alpha (TNF-α) in 
target tissues [75]. 
Activation of the Ang II signaling by JAK STAT pathway can occur in 
the mesangial cells, hepatocytes, cardiovascular system, renal proximal 
tubular cells, and brainstem astrocytes [25]. In the pathogenesis of 
ARDS, Ang II increases through ACE and drives severe lung failure 
through the Angiotensin II type I receptor (AT1R) [29]. AT1R recruits 
and phosphorylates JAK2, and, based on the target cell, one of the STAT 
is phosphorylated by activated JAK2 (F. et al., 2020). In COVID-19, 
macrophage infiltration into the lung tissue occurs, which is accompa-
nied by the apoptosis of epithelial cells and pneumocytes. Infiltration of 
macrophages into alveolar cavities may be mediated by monocyte che-
moattractant protein-1 (MCP-1) through transforming growth factor 
beta 1 (TGF-β1) and TNF-α, which leads to cytokine production (He 
et al., 2008). Markers of infiltration include the neutrophil chemokine 
receptor 2 (CXCR2), along with monocyte chemotactic protein (MCP-1/ 
CCL2) and its receptor chemokine receptor type 2 (CCR2). NF-kB 
signaling pathway genes (NFKBIA, NFKB1, RELA, NFKB2) were upre-
gulated in COVID-19 patients [30,77]. Cytokine storm is emerging as 
one of the mechanisms leading to ARDS, defined as the release of high 
concentrations of pro-inflammatory cytokines, including IL-1, IL-2, IL-6, 
IL-7, IL-10, TNF-α, granulocytecolony stimulating factor, interferon 
(IFN)-γ inducible protein-10 (IP-10), MCP-1, and macrophage inflam-
matory protein 1-α (MIP1-α) by immune cells. The cytokine storm ini-
tiates a fulminant response by the immune system, leading to 
multisystemic organ dysfunction and even death in severe COVID-19 
[13]. Elevated concentrations of inflammatory markers including IL-6, 
c-reactive protein (CRP), procalcitonin (PCT), and erythrocyte sedi-
mentation rate (ESR) are detected in fatal cases [96]. Cytokine storm on 
the IL-6/TNF-α axis appears to be mediated likely through the phos-
phorylation of the NF-kB subunit p65. In SARS-CoV infection, the viral 
spike protein induces the activation of NF-kB via the nuclear factor of 
kappa light polypeptide gene enhancer in B-cells inhibitor, alpha (IkB-α) 
degradation, resulting in the production of IL-6 and TNF-α [84]. The 
viral nucleocapsid protein of SARS-CoV can also bind to the NF-kB 
regulatory element on the IL-6 promoter, with the highest activity in 
the presence of the p65 subunit [99]. Regulatory elements in the ACE2 
gene control the transcription of PIR (pirin), a negative regulator of NF- 
kB subunit RELA (p65). SARS-CoV-2 disruption of ACE2 has been pro-
posed to decrease PIR expression [26]. PIR has been proposed to act as a 
reversible switch that provides the NF-kB response with changes in the 
level of redox (oxidative stress) in the cell nucleus [50]. Repression of 
PIR ablates the inhibition of IL-6 expression [90]. Studies in addressing 
bronchoalveolar lavage fluid (BALF) show promise since findings in the 
blood do not essentially describe the events occurring in tissues directly 
affected by the infection [28]. 
In a study conducted by Xiong et al [93], a comparison of the cyto-
kine genes demonstrated that in BALFs of three COVID-19 patients, the 
genes for IL-10, CCL2/MCP-1 (together with its CCR2 receptor), 
macrophage inflammatory protein-1α (CCL3/MIP-1A) together with its 
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CCR5 receptor, interferon gamma-induced protein 10 (CXCL10/IP-10), 
and macrophage inflammatory protein-1 beta (CCL4/MIP1β) increased. 
Interestingly, in PBMC, genes related to apoptosis, autophagy, and p53 
pathways increased; a finding that could be related to the lymphopenia 
found in the COVID-19 patients. Moreover, IL-6 transcripts were not 
enhanced in PBMCs, although the patients had high plasma contents of 
such cytokine, suggesting that circulating IL-6 could have been pro-
duced in the lungs, either by alveolar epithelial cells or by recruited 
inflammatory cells. 
One study showed that in BALFs of patients with severe COVID-19, 
macrophages were predominant, with a minor proportion of T and 
natural killer (NK) cells, compared with moderate COVID-19 patients. 
Fatty acid binding protein 4 (FABP4) produced by alveolar macrophages 
was preferentially expressed in healthy controls and in patients who had 
a moderate COVID-19 infection, while FCN1 (monocyte-derived) and 
SPP1 (pro-fibrotic) were expressed in patients with severe COVID-19. 
Besides, these results suggest that during COVID-19 infection, inflam-
matory monocytes (FCN1+) are recruited from the circulation into the 
lungs, where they differentiate into SPP1+ macrophages, constituents of 
the severe inflammatory reaction. Analysis of the BALF transcriptome 
displayed that T and NK cells increased in COVID-19 patients in com-
parison with healthy controls, which according to their gene expression 
can be classified in NK, cluster of differentiation 8 (CD8), (cluster of 
differentiation 4 (CD4), Tregs, and proliferating cells. Interestingly, 
genes related to activating molecules, migration, calcium signaling, and 
effector molecules were highly expressed by CD8 cells in patients who 
had a moderate COVID-19 infection compared with those with severe 
COVID-19 infection; this further supports the role of CD8 cells in the 
elimination of the virus and their subsequent protective immunity. In 
contrast, higher expression of genes related to proliferation, energy 
generation, and initiation of translation was seen in patients with severe 
disease, suggesting that in patients with moderate COVID-19 infection, 
CD8 cells are more differentiated and efficient, while in severe infection, 
T cells are in a proliferative stage. Furthermore, the finding that the TCR 
repertoire is higher in CD8 than CD4 cells suggests a larger clonal 
expansion of the CD8 cells taking part in the resolution of the infection 
[47]. The results of Zhou et al. [102] demonstrated that in the BALF of 
patients with COVID-19, the differentially expressed genes (DEGs) 
included more pro-inflammatory chemokines, such as CXCL2, CXCL8, 
and, CXCL17, as well as the CXCR2 receptor, essential to neutrophil 
recruitment, and CCL2 and CCL7, needed for monocyte recruitment. 
Besides, in patients with COVID-19, IL-1b, antiviral interferon stimu-
lated genes (ISGs), and genes related to the TNF, IL-17, and NF-kB 
signaling pathways increased. Furthermore, the cellular analysis 
demonstrated an enhanced neutrophil to lymphocyte ratio (NLR) in 
COVID-19 patients compared with other pneumonias patients. 
3. MiRNA biogenesis 
The miRNA is referred to a short RNA originated from a precursor 
with a stem-loop structure that interferes mainly with the regulation of 
gene expression by targeting mRNAs and dissecting or inhibiting their 
expression [87] (Fig. 1). 
Seven nucleotides situated at the 5′-end of mature miRNA molecules 
comprise what is known as the seed region, which binds to the non- 
coding end [3′-untranslated region (3′- UTR)] of its complementary 
mRNA. Thus, the miRNA identifies the target mRNA molecule. If the 
miRNA fully binds to the target mRNA, it will completely degrade the 
mRNA, while in case of an incomplete binding to the target mRNA, the 
miRNA will inhibit the translation of the mRNA [87]. 
The miRNA-coding genes make up around 3% of the human genome. 
Hence, around 30–92% of human genes are likely to be regulated by 
miRNAs. The regulatory role of the miRNA gene is now well documented 
[100]. The function of miRNAs is essential for the development of 
different physiological systems and the maintenance of their cell ho-
meostasis and normal functioning. Numerous miRNA variants play roles 
in various biological processes such as cell signaling regulation, differ-
entiation, cell cycle, growth, apoptosis, tumorigenesis, and neurogenesis 
[7,6,9,34,48]. MiRNAs comprise about 1–5% of the animal genomes, 
and it is estimated that there are approximately 800–1000 miRNAs in 
the human genome and that over one-third of the protein-coding 
genome is regulated by miRNAs. Each miRNA can target and regulate 
the mRNA transcription of hundreds of downstream genes. A miRNA can 
have several target sites in the mRNA of a downstream gene, while a 
mRNA can be targeted by multiple miRNAs. Therefore, miRNAs 
contribute to a recently known level of gene expression regulation and 
play an important role in biological processes, function of almost all 
tissues and organ systems in the body, and development of various 
diseases [87]. 
4. MiRNAs in SARS-CoV-2 infection 
Coronaviruses are a large family of viruses that are known to cause 
illness ranging from the common cold to SARS [4]. MiR-155 augmented 
antiviral T cell responses including cytokine production, cytotoxic ac-
tivity, and homing to the central nervous system (CNS) in coronavirus- 
Fig. 1. MiRNA biogenesis. The biogen-
esis of miRNAs begins with the produc-
tion of the pri-miRNA transcript. The 
microprocessor complex which is con-
sisted of Drosha and DiGeorge Syndrome 
Critical Region 8 (DGCR8), generates the 
pre-miRNA via cleaving the pri-miRNA. 
The pre-miRNA is exported to the cyto-
plasm in an Exportin5/RanGTP- 
dependent manner and processed to 
form the mature miRNA duplex. Even-
tually, either the 5p or 3p strands of the 
mature miRNA duplex is loaded into the 
Argonaute (AGO) family of proteins to 
form a miRNA-induced silencing com-
plex (miRISC) and regulates gene 
expression [65].   
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induced neurologic disease model [22]. The human coronaviruse OC43 
nucleocapsid protein potentiates NF-kB pathway activation. It has been 
demonstrated that miR-9 is capable of diminishing NF-kB translation by 
targeting its 3′ UTR region. SARS, a relatively rare disease, is caused by 
severe acute respiratory syndrome coronavirus (SARS-CoV or SARS- 
CoV-1). This is an acute infectious disease with a significant mortality 
rate and common clinical features such as pulmonary fibrosis and pul-
monary insufficiency [78]. Induction of miR-574 and miR-214 expres-
sion was reported in bronchoalveolar stem cells infected by SARS-CoV 
[69]. The expression of miR-223 and miR-98 was downregulated in 
BASCs through some viral nucleocapsid proteins controling pro- 
inflammatory cytokine secretion [57]. 
A recent study showed that the response to tocilizumab which was 
tested on COVID-19-induced cytokine storm is associated with a sig-
nificant reduction of plasma IL-6 and a significant elevation of miR-146a 
levels. However, COVID-19 patients who did not respond to this anti-
body had lower serum levels of miR-146a-5p after the treatment [73]. 
The other established effect of miRNAs on coronavirus is the regu-
lation of ACE2 expression. This enzyme catalyzes the conversion of Ang I 
into Ang 1–9 and II into 1–7. Several studies have confirmed the po-
tential role of ACE2 in COVID-19-related diseases [1,32,97]. MiR-125b 
acts as a negative regulator targeting 3′UTR of ACE2 mRNA. Similarly, 
miR-18 was disregulated in ACE-associated nephropathy, which offers 
antimiR-18 as a novel therapeutic candidate in COVID-19 related dis-
eases [88]. 
Computational prediction analysis detected that 29 miRNA pre-
cursors in the SARS-CoV-2 genome can target host genes involved in 
vital signaling pathways such as Wnt and epidermal growth factor 
(EGF)-receptor signaling pathways. On the other hand, some SARS-Cov- 
2-encoded genes could be targeted by host miRNAs. The products of 
these genes are essential in the entrance and replication of the virus. For 
example, has-miR-203b-3p and has-miR-148-3p targeted ORF genes that 
play key roles in viral replication. Liu et al. recruited bioinformatics 
approaches and showed that miR-147-3p derived virus through serine 2 
as a transmembrane protease, facilitating entrance into gastrointestinal 
cells. STAT1 is an essential element in IFN signaling and anti-virus de-
fense. Panther analysis reported that some miRNAs derived from SARS- 
CoV-2 might suppress STAT1 protein [74]. Analyszing the tran-
scriptomic data of human alveolar and bronchial epithelial cells 
demonstrated that the CSF1 gene, a known target of miR-1207-5p, is 
over-expressed during SARS-CoV-2 infection. CSF1 promotes macro-
phage migration and activation and may be associated with the acute 
inflammatory response in severe COVID-19 [12]. Yousefi et al. 
employed Viruses- STRING, a protein–protein interaction database, and 
illustrated that the signaling pathway through TGF-beta with the largest 
numbers of involved genes plays a crucial role during SARS-CoV-2 
infection [94]. 
Several reports have confirmed that diabetes increases the severity 
and mortality of COVID-19 infection [42,66]. It was indicated that the 
upregulation of the cardiac miR-133a levels in the diabetic heart 
diminished cardiac lipid accumulation. Thus, miR-133a is a promising 
candidate for investigating its role in heart failure in patients with dia-
betes and COVID-19 [40]. Upregulation of miRNA 197–5p was 
described in cardiovascular patients, and miRNA 197–5p was proposed 
as a prognostic and risk factor of such cardiac events. MiRNA 197–5p 
also has a role in defense against SARS-CoV-2 infection. Therefore, a 
higher COVID-19 mortality rate and susceptibility in patients with the 
cardiovascular disease may be connected to the loss of the miRNA 
197–5p binding site across the SARS-CoV-2 genome [5]. On the other 
hand, Balme et al.’s prediction study found that an increased expression 
of hsa-miR-1307-3p might lead to a reduction in SARS-CoV-2 replication 
and had a high affinity to SARS-CoV-2 genome 3′UTR and high 
expression in lung tissue. The hsa-miR-1307-3p could promote glyco-
genesis and glucose uptake by inhibiting protein kinase c (PKC) and 
extracellular signal-regulated kinase (ERK), which are inhibitors of RS1 
and indirectly reduce blood sugar [10]. 
In the field of miRNA-based antiviral therapies, Hum et al. intro-
duced three microRNAs (miR-16, miR-200, and miR-24) that can serve 
as modulating approaches in SARS-CoV-2 infection [33]. It was 
demonstrated that miR-24 had a crucial role in furin regulation. It is a 
serine protease that activates proteolytic function and the host-cell 
entrance of some respiratory viruses and also increases TGF-β1secra-
tion that leads to lung damage [61]. MiR-200 binds to a highly 
conserved region of the ACE2 3′-UTR gene as a major regulator of heart 
function [33], and miR-16 induces apoptosis by downregulating BCL2 
[21]. Suppression of miR-16 was also found to increase mitochondrial 
reactive oxygen species (ROS) generation and toll-like receptor 4 (TLR4) 
expression [63]. 
All in all, it seems that the identification of host and virus miRNAs 
may bring about perspective therapeutic strategies for the control of 
viral pathogenicity and its side effects in COVID-19 related diseases 
[24]. 
5. Further hypotheses about the role of miRNAs in regulating 
signaling pathways involved in COVID-19 pathogenesis 
Potential targets of a number of most important miRNAs (miR-9, 
miR-98, miR-223, and miR-214), whose expression is predicted to 
change in host cells infected with COVID-19 [76], were specified using 
bioinformatics analysis and shown in Table 1. Moreover, the in-
teractions of protein targets with each other and with the mentioned 
miRNAs are shown in Figs. 2-5. 
5.1. The role of miRNAs in regulating JAK-STAT signaling pathway 
After the attachment of the spike protein of coronaviruses to the 
ACE2 receptor of host cells, the RNAs of the viral genome are detected 
by toll-like receptors (TLRs), especially TLR3 and TLR 7/8, as well as 
(RIG-I)/MDA5, which is a cytosolic RNA sensor, leading to the activa-
tion of antiviral responses through the activation of different signaling 
pathways including NF-kB and JAK-STAT [58]. The expression of TLRs 
is regulated by different miRNAs. The 3′untranslated region (3′ UTR) of 
TLR7 is directly targeted by miR-9-5p and miR-223-5p. TLR8 is also 
directly targeted by miR-98-5p and miR-223-3p. Interestingly, the 
activation of TLR2 and TLR7/8 in the MyD88-dependent pathway 
increased the expression of miR-9 in polymorphonuclear neutrophils 
(PMN) and monocyte cells [11]. 
Various cytokines including interleukins IL-10, IL-7, IL-6, IL-4, and 
IL-2 and interferons IFN-α, IFN-β, IFN-γ, and granulocyte colony- 
stimulating factor (GCS-F) induce different biologic effects through 
activating the JAK/STAT pathway [14]. IL-6 that severely increases in 
COVID-19 patients and plays a significant role in acute inflammatory 
response is a major potential target of miR-98-5p, miR-9-5p, and miR- 
223-3p. Moreover, it is predicted that the expression of IL6R, the 
membrane receptor of IL-6, is also partially regulated by miR-98-5p. Via 
activating various cells expressing glycoprotein 130 (GP130) and IL-6 
receptors, IL-6 activated JAK/STAT pathway [19]. The IL-6/JAK/ 
STAT pathway is highly activated in acute inflammation, and the 
excessive activity of this pathway in COVID-19 patients likely exacer-
bates the inflammatory responses of the host. Interestingly, the activa-
tion of this pathway in a positive feedback loop produced IL-6 [14]. 
Investigating samples of osteoarthritis (OA) patients indicated that miR- 
9-5p elevated the expression of IL-6 in human chondrocytes through 
inhibitng monocyte chemotactic protein-1-induced protein-1 (MCPIP1) 
[56]. 
The results of a study on the peripheral blood mononuclear cells 
(PBMCs) samples of systemic lupus erythematosus (SLE) patients 
showed that miR-98-5p directly targeted IL-6 and inhibited the pro-
duction of inflammatory cytokines and cell proliferation through IL-6/ 
STAT3 pathway [95]. Moreover, the results of a dual luciferase re-
porter assay in human adipose stem cells indicated that miR-223-3p 
regulated the expression of inflammatory cytokines IL-6 and STAT3 (J. 
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[91]. Furthermore, the results of another study showed that miR-223-3p 
might be able to increase the expression of IL-6 in synoviocytes through 
the downregulation of IL-17 D receptor [64]. Note that miR-223-3p af-
fects the secretion of IL-6 in mast cells via regulating insulin growth 
factor I receptor/phosphatidylinositol-3-kinase (IGF1R/PI3K) signaling 
pathway [83]. The GP130 (IL6ST) receptor is also targeted by miR-223- 
5p, miR-223-3p, and miR-9-5p. The results of an in vitro study on mouse 
NPCs demonstrated that miR-9 directly targeted LIFR beta, IL6ST 
(GP130), and JAK1 genes, lowered their expression, and thus inhibited 
astrogliogenesis in these cells [101]. A research on Kawasaki disease 
(KD) mouse found that the increased expression of miR-223-3p, which is 
an important regulatory factor in endothelial damage to the KD, lowered 
the expression of IL6ST [85]. On the other hand, angiotensin II that is 
produced locally in the inflamed vessels leads to the production of IL-6 
after attachment to angiotensin II receptor through activating JAK/ 
STAT pathway. AT1R is directly targeted by miR-98-3p and miR-223-3p. 
IL-10, acting as a key mediator in immune response, and interleukin- 
4 receptor are also directly targeted by miR-98-5p. The results of a study 
on HEK-293 and RAW 264.7 cell lines demonstrated that miR-98-5p 
directly targeted the 3′ UTR of IL-10 and inhibited its expression at 
the post-transcriptional level [52]. IFNA21, a member of type 1 IFN 
family, is directly targeted by miR-223-3p. An in vitro functional study 
in macrophages demonstrated that miR-223-3p increased the produc-
tion of type 1 IFN via directly targeting FOXO3. Moreover, a type 1 IFN 
raised the expression of miR-223-3p in a positive feedback loop [17]. 
Furthermore, miRNAs could also affect the expression of IFN receptors 
at the post-transcriptional level. IFNAR1 (interferon alpha receptor 1) is 
a direct target of miR-98-5p, miR-98-3p, miR-9-3p, and miR-214-3p. 
Interferon gamma receptor 1(IFNGR1) is also targeted by miR-9-3p 
and miR-98-5p. The expression of genes in the downstream signaling 
pathway of IFN receptors, JAK/STAT, is affected by many miRNAs 
[41,89]. JAK1, a member of the Janus kinase (JAK), a family of non- 
receptor tyrosine kinases, is directly targeted by miR-9-5p. Moreover, 
JAK3, as another member of this family, is targeted by miR-9-5p, miR-9- 
3p, and miR-214-5p. The findings of an in vitro functional study indi-
cated that the 3′ UTR region of JAK1 and MMP-13 genes was a direct 
target of miR-9 in human atherosclerosis models and miR-9 was able to 
inhibit downstream NLR family pyrin domain containing 3 (NLRP3) 
inflammasome through targeting JAK1 [86]. 
STAT transcription factors, which are phosphorylated and activated 
after the activation of JAK proteins, are the regulatory targets of miR-
NAs. The expression of STAT1 is regulated by miR-9-3p and miR-223-3p, 
and the expression of STAT2 is regulated by miR-98-5p, miR-223-3p, 
and miR-214-3p. In addition, STAT3 and STAT5A are also directly tar-
geted by miR-98-5p and miR-223-3p, respectively. A luciferase reporter 
assay in human T cells revealed that miR-150 and miR-223 specifically 
targeted the 3′UTR of STAT1 and consequently reduced the expression 
of this gene and inhibited the downstream signaling pathway indepen-
dent from or dependent on IFN [62]. Microarray analysis results in the 
nucleus pulposus tissues of patients with intervertebral disc degenera-
tion showed that the miR-98 expression significantly declined. 
Furthermore, the results of an in vitro gain-of-function study indicated 
that miR-98 was able to target STAT3 and inhibit IL-6/STAT3 signaling 
pathway in IDD patients [36]. In addition, the knockdown of miR-98 in 
nasopharyngeal carcinoma cells reduced the expression of STAT3 pro-
tein and consequently inhibited the proliferation, migration, and 
Table 1 
Potential targets of miR-9, miR-98, miR-223 and miR-214 involved in COVID19 
pathogenesis.  




IL6R miR-98-5p Interleukin 6 receptor 
IL10 miR-98-5p Interleukin 10 
STAT2 miR-98-5p,miR-214-3p, Signal transducer and activator of 
transcription 2  
miR-223-3p  
STAT3 miR-98-5p Signal transducer and activator of 
transcription 3 
IFNAR1 miR-98-5p,miR-98-3p, miR- 
9-3p, miR-214-3p 
Interferon alpha and beta receptor 
subunit 1 
IFNGR1 miR-98-5p, miR-9-3p Interferon gamma receptor 1 
PIAS4 miR-98-5p Protein inhibitor of activated STAT 4 
CCL3 miR-98-5p C-C motif chemokine ligand 3 
EDA miR-98-5p Ectodysplasin A 
LYN miR-98-5p, miR-223-3p LYN proto-oncogene, Src family 
tyrosine kinase 
PLCG2 miR-98-5p Phospholipase C gamma 2 
TAB2 miR-98-5p,miR-98-3p, miR- 
9-3p, miR-214-5p 
TGF-beta activated kinase 1/MAP3K7 
binding protein 2 
BIRC3 miR-98-5p Baculoviral IAP repeat containing 3 
IKBKE miR-98-5p Inhibitor of nuclear factor kappa B 
kinase subunit epsilon 
BCL2 miR-98-5p, miR-9-5p B-cell lymphoma 2 
BCL2L1 miR-98-5p BCL2 Like 1 
NFKB2 miR-98-5p Nuclear factor kappa B subunit 2 
LTBR miR-98-5p Lymphotoxin beta receptor 
TLR8 miR-98-5p Toll like receptor 8 
TRAF1 miR-98-5p TNF receptor associated factor 1 
TRIM25 miR-98-3p, miR-223-3p Tripartite motif containing 25  
miR-214-5p, miR-9-5p  
AGTR1 miR-98-3p, miR-223-3p Angiotensin II receptor type 1 
IL4R miR-98-3p Interleukin 4 receptor 
IL6ST miR-223-3p,miR-223-5p, 
miR-9-5p 
Interleukin 6 signal transducer 
STAT1 miR-223-3p, miR-9-3p Signal transducer and activator of 
transcription 1 
STAT5A miR-223-3p Signal transducer and activator of 
transcription 5A 
ERC1 miR-223-3P,miR-214-3p ELKS/RAB6-interacting/CAST family 
member 1 
NFKBIA miR-223-3p NFKB inhibitor alpha 
PARP1 miR-223-3p Poly(ADP-ribose) polymerase 1 
TLR8 miR-223-3p, miR-98-5p Toll like receptor 8 
ICAM1 miR-223-3p Intercellular adhesion molecule 1 
EDA2R miR-223-5p Ectodysplasin A2 receptor 
IFNA21 miR-223-5p Interferon alpha 21 
MYD88 miR-223-5p,miR-214-5p Myeloid differentiation primary 
response 88 
TRAF5 miR-223-5p TNF receptor associated factor 5 
TNFSF14 miR-223-5p TNF superfamily member 14 
TLR7 miR-223-5p,miR-9-5p Toll like receptor 7 
RIPK1 miR-223-5p, miR-9-5p Receptor interacting serine/threonine 
kinase 1 
IL17D miR-9-5p Interleukin 17D 
JAK1 miR-9-5p Janus kinase 1 
JAK3 miR-9-5p, miR-214-5p, Janus kinase 3  
miR-9-3p  
STAM miR-9-5p Signal transducing adaptor molecule 
PIAS3 miR-9-5p, miR-214-5p Protein inhibitor of activated STAT 3 
EP300 miR-9-5p E1A binding protein p300 
KLHDC10 miR-9-5p Kelch domain containing 10 
TRAF3 miR-9-5p TNF receptor associated factor 3 
TRAM1 miR-9-5p Translocation associated membrane 
protein 1 
NFKB1 miR-9-5p Nuclear factor kappa B subunit 1 
CFLAR miR-9-5p CASP8 and FADD like apoptosis 
regulator 
TAB3 miR-9-5p TGF-beta activated kinase1 and 
MAP3K7 binding protein 3 
IL17A miR-9-3p Interleukin 17A 
IRAK4 miR-214-3p Interleukin 1 receptor associated 
kinase 4  
Table 1 (continued ) 
Gene miRNA Full name of the genes 
TRAF2 miR-214-5p TNF receptor associated factor 2 
LTA miR-214-5p Lymphotoxin alpha 
CARD14 miR-214-3p Caspase recruitment domain family 
member 14 
TRADD miR-214-3p TNFRSF1A associated via death 
domain  
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invasion of these cells through miR-98/STAT3 signaling pathway [51]. 
In another study, it was shown that the induced underexpression of miR- 
223 in murine macrophages activated its direct target, STAT3, and thus 
significantly increased the production of pro-inflammatory cytokines IL- 
6 and IL-1 β [18]. The increased expression of miR-223 in mouse em-
bryonic fibroblasts and HEK293 cells lowered the expression of different 
genes in the cell survival or death pathway including STAT5A, and more 
comprehensive analyses verified STAT5A as a direct target of miR-223 in 
this study [68]. 
MiRNAs are able to indirectly affect signaling pathways activated by 
cytokines and thus innate and adaptive immune responses through 
targeting the JAK/STAT pathway regulators [67]. PIAS3, an inhibitor of 
STAT3 transcription factor in cell nucleus, was identified as a direct 
target of miR-214 and miR-9-5p. Increasing the expression of miR-9-5p 
by reducing the expression of protein inhibitor of activated STAT 3 
(PIAS3), an inhibitor of JAK/STAT pathway, increased the expression of 
STAT3, resulting in an increase in the population of Th17 cells in MS 
patients [55]. Furthermore, miR-9 and miR-181a led to the development 
of early-stage myeloid-derived suppressor cells (eMDSCs) in breast 
cancer through inhibiting the function of negative regulators of JAK/ 
STAT pathway, SOCS3, and PIAS3 [37]. Histone acetyltransferase 
EP300 that functions in chromatin remodeling and transcription regu-
lation of the target genes of JAK/STAT pathway is also a direct target of 
miR-9-5p. The overexpression of miR-9 increased the expression of miR- 
132 and indirectly affected the expression of the direct target genes of 
miR-132, namely phosphatase and tensin homolog (PTEN), FOXO3A, 
and EP300, and apoptosis in rheumatoid arthritis [46]. STAM, an 
adaptor molecule playing a role in facilitating the transcription of spe-
cific target genes of JAK/STAT signaling pathway [71], and SLIM, a 
nuclear E3 ubiquitin ligase that is a negative regulator of STAT pathway 
[80], are targets of miR-9-5p. Finally, JAK/STAT pathway activates the 
transcription of numerous genes in the inflammatory pathway, 
including ACE2, IL-8, IL-6, IL-2, IL-17, IL-1β, CSF3, CSF2, CCL3, TNF-α, 
and IFN-γ, which are regulated by different miRNAs [14,53]. IL-7 was 
identified as a direct target of miR-9-5p and miR-9-3p, and also, CCL3 
was identified as a direct target of miR-98-5p and miR-223-3p. The re-
sults of high-throughput sequencing demonstrated that the expression of 
miR-98-5p severely increased in immunoglobulin a nephropathy (IgAN) 
patients and this miRNA was able to directly target CCL3, and when its 
expression was inhibited, increase the expression of IL6 [49]. Through 
directly targeting CCL3 and IL-6, miR-223 controls the migration of 
inflammatory cells to the lung tissue and the formation of stable local 
inflammation in tuberculosis disease [23]. 
5.2. The role of miRNAs in regulating NF-kB signaling pathway 
As mentioned earlier, RNAs of the viral genome are diagnosed via 
toll-like receptors (TLRs), inducing various antiviral responses via acti-
vating various signaling pathways such as NF-kB. 
Investigating the performance of miR-223 in the regulation of the 
inflammatory responses activated through TLRs in macrophages indi-
cated that the expression of miR-223 decreased in TRL ligand stimula-
tion. The reduced expression of miR-223 via the increased expression of 
Ras homolog family member B (RhoB) led to the activation of the NF-kB 
pathway [98]. 
NF-kB transcription factor plays an important role in innate and 
adaptive immunity. In normal conditions, NF-kB is inhibited by IKB 
proteins in cytoplasm. Various cellular stimuli including pathogens lead 
to the induction of NF-kB and the displacement of its nucleus through 
the phosphorylation and ubiquitin-dependent proteasomal degradation 
of the inhibitor of IKB. NF-kB leads to the transcription of a wide variety 
of pro-inflammatory cytokines, chemokines, anti-apoptotic proteins, 
and stress-response proteins [14]. NF-kB pathway in lung inflammatory 
immunopathology, which is induced after infection with respiratory 
viruses such as SARS-CoV, is very active (DeDiego et al., 2014; Smits 
et al., 2010). 
Genes regulating NF-kB signaling pathway are the regulatory targets 
of different miRNAs. EDA, a cytokine activating NF-kB pathway after 
attachment to ectodysplasin A receptor (EDAR) is a direct target of miR- 
98-5p. Lyn, a member of Src family of tyrosine kinases that activates NF- 
kB via activating PI3K signaling pathway, is a target of miR-98-5p [81]. 
PLCG2 is also directly targeted by miR-98-5p. Cytokines such as TNF and 
TGF- β1 can activate PLCG2 and lead to the activation of ERK and NF-kB 
signaling pathways [54]. On the other hand, miR-223 and miR-214 can 
directly target 3′ UTR of ERC1 gene. The miRNA microarray profiling 
results demonstrated that the expression of miR-223-3p increased by 
13.01 times in patients with ulcerative colitis, and the results of in silico 
prediction tools determined ERC1 as one of the most important targets 
of this miRNA in NF-kB pathway [82]. MyD88, an adaptor protein in NF- 
κB signaling pathway, is also targeted by miR-214-5p and miR-223-5p. 
The increased expression of miR-214 by targeting MyD88 reduced the 
production of inflammatory cytokines in V. harveyi bacterial infection 
Fig. 2. Potential targets of miR-223, miR-98, miR-9, and miR-214 in JAK/STAT pathway. The JAK/STAT signaling pathway is a transducer of a wide variety of 
signals for development and homeostasis in animals from humans to flies. In mammals, this pathway is the main mechanism of signal transduction from growth 
factors and cytokines. Following the binding of a cytokine to a receptor, the JAK tyrosine kinase activates STAT. Upon the activation of STAT, it is dimerized and 
transferred to the nucleus, leading to the regulation of the transcription of target genes. The targets of the miR-223, miR-98, miR-9, and miR-214 in these pathway are 
shown using red arrows (KEGG PATHWAY database). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
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and prevented the exacerbation of inflammation [20]. Through the 
utilization and phosphorylation of IRAK and TRAF6 complexes, MyD88 
activates MAPK and NF-kB pathways. IRAK4 enzyme, which is an 
important threonine/serine protein kinase in MAPK pathway and TLR- 
mediated immune responses [39], is directly targeted by miR-214. Re-
ceptor-interacting protein kinase 1 (RIPK1) that determines the cell fate, 
death or survival, through NF-kB signaling pathway after receiving a 
wide variety of pro-inflammatory or pro-death cytokines is a target of 
miR-223-5p and miR-9-5p [60]. The results of gene expression analysis 
and luciferase reporter assay showed that the expression of RIPK1 and 
RIPK3 in acute kidney injury induced in C57BL/6 mice increased, and 
miR-223 could directly target 3′ UTR of RIPK3 gene (Huang et al., 2018). 
TNFR1 associated death domain protein (TRADD), an adaptor protein 
mediating cell death and activating NF-kB pathway through interacting 
with TNFRSF1A/TNFR1, is a direct target of miR-214-3p. TRAF2 and 
TRAF5 were identified as targets of miR-214-5p and miR-223-5p, 
respectively. Tumor necrosis factor receptor associated factor-2 
(TRAF2) and tumor necrosis factor receptor associated factor-5 
(TRAF5) lead to the activation of TAK1 via the ubiquitination of IKKγ/ 
NEMO. TAK1 finally activates IKK enzyme and leads to the phosphor-
ylation and deactivation of IκBα and the activation NF-kB pathway [59]. 
MiR-98-5p is capable of directly targeting the epsilon subunit of this 
enzyme (IKBKE). BIRC3 (cIAP2), as a member of the family of proteins 
inhibiting apoptosis by NF-kB pathway, was determined as one target of 
miR-98-5p. TRAF3 was identified as a potential target of miR-214 and 
miR-9-5p. The expression of miR-214 increased in the tissues of osteo-
sarcoma patients as well as osteosarcoma cell lines, and this miRNA was 
capable of directly targeting TRAF3 gene [72]. TAB2, an adaptor protein 
that forms a complex with TAK1 and is necessary for the activation of 
NF-kB pathway, is a target of many miRNAs including miR-9-5p, miR-9- 
3p, miR-98-5p, miR-98-3p, and miR-214-5p. The findings of qRT-PCR in 
ovariectomized rats (OVX-ASCs) suggested the increased expression of 
miR-214. In addition, two new targets of miR-214, CTNNB1 (β-catenin) 
and TAB2, were identified in this study via luciferase reporter assay 
[45]. MiRNAs can directly target the negative regulators of NF-kB 
pathway. In this regard, miR-223-3p is able to directly target NFKB 
Fig. 3. Potential targets of miR-223, miR-98, miR-9, and miR-214 in NFκB pathway. Nuclear factor-kappa B (NF-kappa B) regulates genes played important roles in 
immunity, inflammation and cell survival. There are several pathways resulting in NF-kappa B-activation. The canonical pathway is induced by TNF-α, IL-1 or 
byproducts of bacterial and viral infections. This pathway depends on IKK- mediated IkappaB-alpha phosphorylation on Ser32 and 36, leading to its degradation, 
which allows the p50/p65 NF-kappa B dimer to enter the nucleus and activate gene transcription. The targets of the miR-223, miR-98, miR-9, and miR-214 in these 
pathway are shown using red arrows (KEGG PATHWAY database). (For interpretation of the references to colour in this figure legend, the reader is referred to the 
web version of this article.) 
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inhibitor alpha (NFKBIA). It was shown that notch and NF-kB signaling 
pathways could raise the expression of miR-223, which in turn led to the 
reduced expression of onco-suppressor FBXW7 in T-cell acute lympho-
blastic leukemia [43]. 
Tripartite motif containing 25 (TRIM25) that is a positive regulator 
of NF-kB signaling pathway is targeted by miR-98-3p, miR-9-5p, miR- 
223-3p, and miR-214-5p. PARP1, a DNA polymerase playing an 
important role in the identification of DNA damages and the utilization 
of DNA repair proteins, is a direct target of miR-223-3p. PARP1 leads to 
the activation of NF-kB pathway via a TNF-α-induced pathway. Micro-
array analysis results in JHesoAD1 and esophageal OE33 (adenocarci-
noma) cell lines transfected with miR-223 mimics indicated the reduced 
expression of several target genes including PARP1, CYB5A, and 
SMARCD1. Afterwards, the luciferase assay established that the 3′ UTR 
of PARP1 gene is directly identified by miR-223 [79]. Note that tran-
scription factors NF-kB1 and NF-kB2 are directly regulated by miR-9-5p 
and miR-98-5p. MiR-9 in human monocytes was induced by inflam-
matory cytokines TNF-α and IL-1β, and NF-kB1 was identified as an 
important target of miR-9 in both in silico and experimental in-
vestigations [11]. C-FLIP, Bcl-XL, and BCL2, as target genes of NF-kB 
pathway, are directly targeted by miR-9-5p, miR-98-5p, and both of 
these miRNAs, respectively. The elevated expression of miR-98 through 
targeting Bcl2 gene inhibits the growth and resistance tolerance in 
esophageal squamous cell carcinoma (ESCC) [38]. Moreover, miR-98 
plays a critical role in the pathogenesis of osteoarthritis disease 
through targeting Bcl2 [83]. Furthermore, the expression of miR-98 in 
rat uterus declined in the receptive phase, and miR-98 inhibited 
apoptosis and increased proliferation in this phase by directly targeting 
Bcl-xl [92]. As other target genes of NF-kB pathway, TRAF1 and TRAF2 
are directly targeted by miR-98-5p and miR-214-5p. EDA2R, which is a 
member of TNFR family and activates NF-kB signaling pathway, and 
intercellular adhesion molecule 1 (ICAM1), which is a target of this 
pathway, are also directly targeted by miR-223-5p and miR-223-3p, 
respectively. The targeting of other members of TNFR family by miR- 
223 has been established in the literature. The findings of luciferase 
reporter assay in HEK293 cells or rat cardiac H9c2 cells demonstrated 
that miR-223-5p was able to target 3′ UTR of TNFR1 and DR6 genes 
[70]. LTA and TNFSF14 ligands, activating NF-kB signaling pathway 
after attachment to LT-βR receptor, are targeted by miR-214-5p and 
miR-223-5p, respectively. LT-βR, a member of TNFR family, was also 
identified as a direct target of miR-98-5p. Finally, TRAM1, a member of 
steroid receptor coactivator (SRC) family inducing gene overexpression 
through NF-kB transcription factor, is a target of miR-9-5p. 
Therefore, it can be concluded that the expression of genes in JAK/ 
STAT and NF-kB signaling pathways is significantly affected by miR-9, 
miR-98, miR-223, and miR-214, and these miRNAs may play an 
important role in the pathogenesis of COVID-19. 
6. Discussion 
Multiple destructive inflammatory signaling pathways have been 
implicated in COVID-19 pathogenesis, which leads to multiple-organ 
damages, physiological deterioration, and eventually death. In the cur-
rent study, the results obtained from targeting the aforementioned in-
flammatory pathways in COVID-19 patients were reviewed. It was found 
that NF-kB and JAK-STAT signaling pathways have key roles in 
Fig. 4. Potential interactions between genes involved in the JAK/STAT and NFκB pathways are depicted using the STRING database (string-db.org).  
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inflammation involved in COVID-19 pathogenesis. 
NF-kB signaling pathway genes (NFKBIA, NFKB1, RELA, NFKB2) 
were upregulated in patients with COVID-19 infection. JAK/STAT 
pathway induced various cytokines including interleukins IL-10, IL-7, 
IL-6, IL-4, and IL-2 and interferons IFN-α, IFN-β, IFN-γ, and GCS-F. 
Additionally, we reviewed research works in which miRNAs targeted 
inflammatory signaling pathways involved in the inflammatory dis-
eases. Our study focused on miR-9, miR-98, miR-223, and miR-214, 
which make a unique contribution to the regulation of inflammatory 
pathways related to COVID-19 pathogenesis, and whose target genes are 
related to NF-kB and JAK-STAT pathways. 
Based on the results, TRIM25, which is a positive regulator of NF-kB 
signaling pathway, is targeted by miR-98-3p, miR-9-5p, miR-223-3p, 
and miR-214-5p. PARP1, which leads to the activation of NF-kB 
pathway via a TNFα-induced pathway, is targeted by miR-223-3p. 
Transcription factors NFKB1 and NFKB2 are directly regulated by 
miR-9-5p and miR-98-5p. In addition, TNF-α, IL-1β, and NF-kB1 were 
targeted by miR-9. C-FLIP, Bcl-XL, and BCL2, as target genes of NF-kB 
pathway, are directly targeted by miR-9-5p, miR-98-5p, and both of 
these miRNAs, respectively. TRAF1 and TRAF2 are directly targeted by 
miR-98-5p and miR-214-5p. TNFR family and ICAM1 are also directly 
targeted by miR-223-5p and miR-223-3p, respectively. 
Recently, several miRNA-based treatments have illustrated thera-
peutic promise in clinical trials. These treatments include the use of 
miRNA antagonists to increase the expression of specific proteins that 
are downregulated or miRNA mimics to decrease the expression of 
proteins that induce abnormally [31]. For example, miravirsen was the 
first miRNA-based drug that was successfully applied for hepatitis C 
virus (HCV) infection. This drug suprresses viral RNA levels by seques-
tering miR-122 away from the viral genome [35]. In regard to the de-
livery of miRNA targets, the poor half-life of miRNAs and the toxicity of 
delivery vehicles are obstacles to treatment. Nanoparticles, lipid-based 
carriers, and exosomes are highly recommended for direct delivery 
into the lungs in the clinical setting [16,27]. 
In conclusion, miRNAs are associated with inflammation processes, 
and their target networks provide new knowledge that can pave the way 
for new therapeutic strategies for COVID-19 pathogenesis. In this re-
gard, miR-9, miR-98, miR-223, and miR-214 can be considered as po-
tential targets for new therapeutic strategies in COVID-19 diseases by 
targeting inflammatory pathways. 
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